Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis vaccines CMO joins Arterial

Dr Markus Weissbach becomes clinical trials director

Arterial Capital Management, a life science-focused private equity firm, has appointed Dr Markus Weissbach as clinical trials director and a member of its board.

Dr Weissback brings over 25 years of life science industry experience to the post - with particular expertise in cardiology, infectious diseases and oncology - and is currently chief operating officer at DS Biopharma in Dublin.

He recently served as chief medical officer at Novartis Vaccines and Diagnostics, and chief executive officer of Averion International.

Prior to this Weissbach was a director at Takeda Europe, with responsibility for its clinical research and development unit. He also brings expertise from Knoll, CytoTools Biotech, Vasopharm, Cardiorentis, BernaBiotech and Sunesis.

David Evans, director of Arterial, said: “The ability to convert strong science and supporting data into strong investor returns is what makes an outstanding private equity business.

“The addition of Markus to our team is fantastic news for investors and investees alike.”

21st February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics